Journal
JOURNAL OF CONTROLLED RELEASE
Volume 279, Issue -, Pages 29-39Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2018.04.004
Keywords
-
Funding
- Agencia Estatal de Investigacion (AEI)
- Fondo Europeo de Desarrollo Regional (FEDER) [BIO2016-76063-R]
- AGAUR [2017SGR-229, 2014 PROD 00055, 2017FI_B100063]
- CIBER de Bioingenieria, Biomateriales y Nanomedicina (project NANOREMOTE)
- CIBER de Bioingenieria, Biomateriales y Nanomedicina (project VENOM4CANCER)
- Marato de TV3 foundation [TV32013-132031]
- CIBER (NanoMets3)
- ISCIII FIS [PI15/00272, PI15/00378, PIE15/00028]
- ISCIII
- AECC
- ICREA ACADEMIA award
Ask authors/readers for more resources
Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). Here we describe a new DDS by which pNPs are fabricated as bacterial inclusion bodies (IB), that can be easily isolated, subcutaneously injected and used as reservoirs for the sustained release of targeted pNPs. Our approach combines the high performance of pNP, regarding specific cell targeting and biodistribution with the IB supramolecular organization, stability and cost effectiveness. This renders a platform able to provide a sustained source of CXCR4-targeted pNPs that selectively accumulate in tumor cells in a CXCR4(+) colorectal cancer xenograft model. In addition, the proposed system could be potentially adapted to any other protein construct offering a plethora of possible new therapeutic applications in nanomedicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available